Business Segments · Acquisitions
Specialty Diagnostics — Acquisitions
Over 4 years (FY 2021 to FY 2025), Specialty Diagnostics — Acquisitions shows a downward trend with a -100.0% CAGR.
Analysis
StatementSegment
CategoryGrowth
SignalContext dependent
VolatilityVolatile
First reportedQ1 2015
Last reportedQ4 2025Feb 26, 2026
Rolls up toGoodwill Additions
How to read this metric
Higher spending indicates an aggressive growth strategy, while zero spending suggests a focus on organic growth or integration.
Detailed definition
The total capital expenditure allocated to the purchase of external businesses or product lines specifically integrated...
Peer comparison
Varies significantly based on the M&A cycle of the company compared to peers like Roche or Siemens Healthineers.
Metric ID:
tmo_segment_specialty_diagnostics_acquisitionsHistorical Data
5 years
| FY'21 | FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|---|
| Value | $8M | $0 | $1.74B | $0 | $0 |
| YoY Change | — | -100.0% | — | -100.0% | — |
Range$0 – $1.74B
CAGR-100.0%
Avg YoY Growth-100.0%
Median YoY Growth-100.0%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Thermo Fisher Scientific's specialty diagnostics — acquisitions?
- Thermo Fisher Scientific (TMO) reported specialty diagnostics — acquisitions of $0 in Q4 2025.
- What is the long-term trend for Thermo Fisher Scientific's specialty diagnostics — acquisitions?
- Over 4 years (2021 to 2025), Thermo Fisher Scientific's specialty diagnostics — acquisitions has grown at a -100.0% compound annual growth rate (CAGR), from $8M to $0.
- What does specialty diagnostics — acquisitions mean?
- The amount of money spent to buy other companies or business units for the Specialty Diagnostics segment.